Label: information for the user
Ditropan5 mg tablets
oxibutinina hydrochloride
Read this label carefully before starting to take this medicine, as it contains important information for you.
Ditropan belongs to a group of medications called urinary antispasmodics.
This medication acts on the contractions of the bladder and delays the desire to urinate. It may be used to treat some types of incontinence and other urinary problems.
Ditropan may be used in children aged 5 years or older to treat:
Read carefully the following sections:
Do not take Ditropan
Warnings and precautions
Consult your doctor or pharmacist before starting to take Ditropan.
Be especially careful:
Older patients
Ditropan should be used with caution in older patients because they have a higher risk of experiencing adverse reactions and due to the risk of cognitive decline.
Children
Children under 5 years old
This medication is not recommended for children under 5 years old.
Children 5 years old and older
Children in this age group have a higher risk of experiencing adverse reactions to the product.
Other medications and Ditropan
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Ditropan may affect the absorption of concomitantly administered medications.
Especially, inform your doctor if you are currently using any of the following medications:
Ditropan and alcohol
The simultaneous use of Ditropan and alcohol may increase drowsiness.
Pregnancy and lactation
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
If you are pregnant or suspect you may be pregnant while taking Ditropan, inform your doctor immediately. It is recommended not to take this medication during pregnancy, unless your doctor considers it necessary.
Lactation
Ditropan passes into breast milk. Do not use this medication during lactation. If your doctor considers it necessary, breastfeeding will be interrupted.
Driving and operating machinery
Ditropan may cause drowsiness or blurred vision, so you should exercise caution when performing activities that require mental alertness, such as driving, operating machinery, or performing hazardous work while using this medication.
Abuse and dependence
Oxybutynin dependence has been observed in patients with a history of substance dependence or abuse (see section 4).
Ditropan contains lactose
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Ditropan contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Dosage
Adults
The recommended dose for adults is 3 tablets (15 mg of oxybutynin hydrochloride) per day, divided into three doses, although it may also be taken all at once at the end of the day for nighttime urinary problems. The dose may be increased to 4 tablets (20 mg of oxybutynin hydrochloride) per day and also reduced to a lower maintenance dose.
Use in children and adolescents
Children under 5 years of age
The safety and efficacy of Ditropan in children under 5 years of age have not yet been established.
Children 5 years of age or older
A dose of 2 tablets (10 mg of oxybutynin hydrochloride) per day is recommended. At least 4 hours should pass between doses.
Older adults
In older adults, a dose of 2 tablets per day is usually sufficient.
If you believe the effect of Ditropan is too strong or too weak, consult your doctor or pharmacist.
Administration form
Remember to take your medication. Ditropan should be taken regularly as directed by your doctor throughout the treatment.
Ditropan is only indicated for oral use.
The tablet should be swallowed whole or may be broken and taken with a large amount of liquid to ensure passage through the esophagus. The taste of the tablets is not pleasant.
If you take too much Ditropan
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount taken.
If you have taken too much Ditropan, you may experience some symptoms, such as: restlessness, excitement, psychotic behavior, flushing, decreased blood pressure, respiratory problems, paralysis, and coma.
If you forget to take Ditropan
In case of missed dose, wait for the next one. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Ditropan
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Very common side effects (may affect more than 1 in 10 people):
Dry mouth, constipation, nausea, dizziness, drowsiness, blurred vision, difficulty urinating, dry skin, headache.
Common side effects (may affect up to 1 in 10 people):
Weakness, diarrhea, vomiting, taste disorder (disturbance of the sense of taste), flatulence (gas), states of confusion, atrial arrhythmia, nodal arrhythmia, supraventricular extrasystole, strong and irregular heartbeats, dry eyes, urinary retention, hematuria (presence of blood in the urine), nocturia (need to urinate at night), pyuria (presence of leukocytes in the urine), pharyngitis (inflammation of the pharynx), skin redness.
Uncommon side effects (may affect up to 1 in 100 people):
Abdominal discomfort, anorexia (loss of appetite), decreased appetite, dysphagia (difficulty swallowing), cough, epistaxis (nasal hemorrhage), vulvovaginitis (inflammation of the vulva and vagina).
Rare side effects (may affect up to 1 in 1,000 people):
Phototoxicity (sensitivity to light), thrombocytopenia (reduction in the number of platelets).
Unknown frequency (cannot be estimated from available data):
Gastroesophageal reflux, gastritis, pseudoobstruction in high-risk patients (in elderly patients or patients with constipation and receiving other medications that decrease intestinal motility), hallucinations, agitation, convulsions, anxiety, nightmares, paranoia (distrust, delirium), cognitive disorders especially in elderly patients, symptoms of depression and oxibutinine dependence (in patients with a history of dependence or substance abuse), tachycardia (increased heart rate), arrhythmia, angle-closure glaucoma (increased intraocular pressure), mydriasis (pupil dilation), hypertension intraocular, urinary tract infection,adverse reactions such as generalized cutaneous erythema, urticaria, angioedema (generalized inflammation of feet, hands, throat, lips, and respiratory tract), skin eruptions, hypohidrosis (decreased sweat production), heat stroke, hypersensitivity, muscle disorders (pain, cramps, or weakness).
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store in the original packaging. Store below 30 °C.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not use this medication if you observe that the tablets have a different appearance (for example, if they change color).
Medications should not be disposed of through drains or in the trash.Deposit the containers and medications you no longer need at the SIGRE collection pointof the pharmacy. Ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Appearance of the product and content of the packaging
Ditropan is presented in the form of tablets. Each package contains 60 tablets. The tablets are round, biconvex, light blue in color with a central groove on one face and the engraving “OXB5” on the opposite face.
Holder of the marketing authorization and responsible for manufacturing
Holderof the marketing authorization
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
Responsible for manufacturing
Sanofi Winthrop Industrie
Avenue Gustave Eiffel, 30-36
37100Tours
France
or
Fidelio Healthcare Limburg GmbH
Mundipharmastraße 2
65549 Limburg an der Lahn
Germany
Local Representative
Laboratorios Rubió, S.A.
Industria, 29
Pol. Ind. Comte de Sert
08755 Castellbisbal (Barcelona)
Spain
Other sources of information
The detailed informationof this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.